We had approximately $8.0 million in cash and cash equivalents, and $564,000 in restricted cash as of June 30, 2008. In addition, we expect to receive an additional $3.1 million in October 2008, related to our Lease Termination Agreement. We believe that our cash, cash equivalents and short- term investments will be sufficient to fund our operations at planned levels through the end of 2009.
As previously announced, SCOLR Pharma will host a conference call on August 7, 2008, at 11:30 a.m. (Eastern Daylight Time). Shareholders and other interested parties may participate in the conference call by dialing +1 888 680 0878 (domestic) or +1 617 213 4855 (international) and entering access code 26733631, a few minutes before 11:30 a.m. ET on August 7, 2008. The call will also be broadcast live on the Internet at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.
A replay of the conference call will be accessible two hours after its completion through August 21, 2008, by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering access code 55141034. The call will also be archived for 90 days at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.
About SCOLR Pharma:
Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty
pharmaceutical company. SCOLR Pharma's corporate objective is to combine
its formulation expertise and its patented CDT platform to develop novel
pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT
drug delivery platform is based on multiple issued and pending
|SOURCE SCOLR Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved